Novartis AG

Andrin Oswald, M.D., is CEO of the Novartis Vaccines and Diagnostics Division, a position he assumed in December 2008. He is a permanent attendee of the Executive Committee of Novartis. Before joining Novartis in 2005, Dr. Oswald worked with McKinsey and Company, Switzerland. From 2005 to 2008, he advanced from Assistant to the Chairman and CEO to Head of the Country Pharma Organization (CPO) and Country President for Novartis in South Korea to CEO of Speedel and Global Head of Development Franchises at Novartis Pharma. Dr. Oswald graduated with an M.D. from the University of Geneva, Switzerland, in 1999 and was a delegate of the International Committee of the Red Cross (ICRC) to Nepal from 2002 to 2003.

David Epstein is Head of Novartis Oncology and since December 2008, he also leads the new Molecular Diagnostics unit. He has been a permanent attendee of the Executive Committee of Novartis since December 1, 2008. Before joining Novartis, Epstein was an associate in the Strategy Practice of the consulting firm Booz Allen Hamilton in the United States. He joined Sandoz, a predecessor company of Novartis, in 1989 and held various leadership positions of increasing responsibility for the company, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Head of Novartis Specialty Medicines. He graduated with a B.S. in pharmacy from Rutgers University College of Pharmacy in 1984 and with an M.B.A. in finance and marketing from the Columbia University Graduate School of Business in 1987.

Dr. Vasella joined the Alcon, Inc. board in July 2008 following the closing of the sale of the 24.85 percent minority interest of Alcon, Inc. by Nestlé S.A. to Novartis AG. Since 1996 Dr. Vasella has served as Chief Executive Officer of the Novartis Group and as executive member of the Board of Directors of Novartis AG. In 1999, he additionally was appointed Chairman of the Board of Directors of Novartis AG. Dr. Vasella graduated with an M.D. from the University of Berne in 1979. After holding a number of medical positions in Switzerland, he joined Sandoz Pharmaceuticals Corporation in the U.S.A. in 1988. From 1993 to 1995, Dr. Vasella advanced from Head of Corporate Marketing to Senior Vice President and Head of Worldwide Development to Chief Operating Officer of Sandoz Pharma Ltd. In 1995 and 1996, Dr. Vasella was a member of the Sandoz Group Executive Committee and Chief Executive Officer of Sandoz Pharma Ltd. Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean’s Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors.

Officer (CEO) of the Novartis Consumer Health Division Head of the Novartis Animal Health Business Unit Permanent attendee of the Executive Committee of Novartis January 2009 www.novartis.com George Gunn is CEO of Novartis Consumer Health and of Novartis Animal Health. Gunn has been a permanent attendee of the Executive Committee of Novartis since December 1, 2008. Before joining Novartis, Gunn was President of Pharmacia Animal Health, based in the United States. Prior to Pharmacia, he spent more than 15 years in positions of increasing responsibility in healthcare companies. He worked as a veterinary surgeon for nine years before joining industry. Gunn joined Novartis in 2003 as Head of Novartis Animal Health, North America. In January 2004, he assumed his position as Head of the Animal Health Business Unit. In addition to this role, he was appointed Head of the Consumer Health Division in December 2008. Gunn graduated with a Bachelor of veterinary medicine and surgery degree and a diploma in veterinary state medicine from the Royal (Dick) School of Veterinary Studies in Edinburgh, United Kingdom, in 1973. In 2008 he received an honorary doctorate in veterinary medicine and surgery from the University of Edinburgh.

Jeff George was appointed CEO of Sandoz in December 2008. He has been a permanent attendee of the Executive Committee of Novartis since December 1, 2008. George joined Novartis in the Vaccines Division in January 2007 as Head of Commercial Operations for Western and Eastern Europe and then advanced to Head of Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharma. Before joining Novartis, he was a Senior Director of Strategy and Business Development at Gap Inc. in San Francisco, and was with McKinsey and Company in San Francisco from 2001 to 2004. George graduated with an M.A. from the Johns Hopkins University’s School of Advanced International Studies in 1999, where he studied international economics and emerging markets political economy. He received an M.B.A. from Harvard University in 2001.

Joseph Jimenez is CEO of the Pharmaceuticals Division. He joined Novartis in April 2007 as CEO of the Consumer Health Division and was appointed to his present position in October 2007. He has been a member of the Executive Committee of Novartis since November 1, 2007. Jimenez began his career at The Clorox Company, California, and later served as president of two operating divisions at ConAgra, Nebraska. In 1998, he joined the H.J. Heinz Company, Pennsylvania, and was named President and Chief Executive Officer of the North America business. From 2002 to 2006, he served as President and Chief Executive Officer of Heinz in Europe. Before joining Novartis, he served as a non-executive director of AstraZeneca plc, United Kingdom, from 2002 to 2007, and was an advisor for the private equity organization Blackstone Group, New York. Jimenez graduated with a B.A. from Stanford University in 1982 and earned an M.B.A. from the University of California, Berkeley, in 1984.

Joerg Reinhardt, Ph.D, was named Chief Operating Officer of Novartis on December 1, 2008, and has been a member of the Executive Committee of Novartis since January 1, 2007. Reinhardt joined Sandoz Pharma Ltd. in 1982 and held positions of increasing responsibility in Research and Development for the company. In 1994, he was named Head of Development for Sandoz Pharma Ltd. After the merger that created Novartis in 1996, Reinhardt became Head of Preclinical Development and Project Management for Novartis and assumed the position of Head of Pharmaceutical Development in 1999. From 2006 to 2008, he served as Head of the Vaccines and Diagnostics Division. He also chairs the Board of Directors of the Genomics Institute of the Novartis Foundation in La Jolla, California. Reinhardt graduated with a Ph.D. in pharmaceutical sciences from the University of Saarbruecken, Germany, in 1981.

Leon V. Schumacher is the Group CIO of Novartis and responsible for Information Technology across all divisions worldwide, a position he assumed in January 2009. Leon Schumacher reports to the Chief Operating Officer of Novartis. Before joining Novartis, Schumacher was the CIO of Arcelor Mittal in the Americas, the world-leading steel company. Prior to the merger of Arcelor and Mittal Steel, he was the Group CIO for Mittal Steel Company in Rotterdam, the Netherlands. Since 1993, Schumacher has built his international career by holding senior positions of increasing responsibility in operations, finance, strategy, logistics and IT. Among others, this has included companies in the steel industry in the US and Europe, such as the internet trading venture Global Steel Exchange, Arcelor International and Mittal Steel. Schumacher graduated with a masters degree in electrical

Raymund Breu, Ph.D., is Chief Financial Officer of Novartis AG. He assumed this position when Novartis was created in 1996. He has been a member of the Executive Committee of Novartis since 1996. Breu joined the Treasury Department of the Sandoz Group in 1975. In 1982 he became Head of Finance for the Sandoz affiliates in the United Kingdom. In 1985 he was appointed Chief Financial Officer of Sandoz Corporation in New York, where he was responsible for all Sandoz Finance activities in the United States. In 1990 he became Group Treasurer of Sandoz Ltd., Basel, Switzerland, and, in 1993, Head of Group Finance and Member of the Sandoz Executive Board. He is also a member of the Board of Directors of Swiss Re and the Swiss takeover commission. Breu graduated from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, with a Ph.D. in mathematics.

Andreas Rummelt, Ph.D., is Group Head of Quality Assurance and Technical Operations, a position he assumed in December 2008. Rummelt has been a member of the Executive Committee of Novartis since January 1, 2006. He joined Sandoz Pharma Ltd. in 1985 and held various positions of increasing responsibility in Development. In 1994, he was appointed Head of Worldwide Technical Research and Development, a position he retained following the merger that created Novartis in 1996. From 1999 to 2004, Rummelt served as Head of Technical Operations of the Novartis Pharmaceuticals Division and from 2004 to 2008 as Head of Sandoz. Rummelt graduated with a Ph.D. in pharmaceutical sciences from the University of Erlangen-Nuernberg, Germany.

Ann Bailey was named Head of Corporate Communications in April 2005. Before taking on this role, she was Head of the Global IQP Program Office, where she was responsible for developing and implementing the global Pharma IQP initiative, a project-based performance improvement initiative focused on continuous improvement through new skills and knowledge. Prior to leading the Global IQP Program Office, Ann served as Head of Pharmaceutical Operations – France. In this role, she oversaw manufacturing, quality assurance and logistics for Novartis pharmaceutical products within France. Her leadership led to the site becoming the global manufacturing Center of Excellence for liquids and suppository products, with consistently strong customer service levels and quality performance. Ann began her Novartis career in 1982 with the company's Consumer Health division in the Over-the-Counter (OTC) business. She also served in numerous operational management positions in OTC, Animal Health, Agro and Pharma. Following the Ciba-Sandoz merger in 1996, Ann became Head of Global Quality Operations – Americas Region, where she established a strong relationship and reputation with the U.S. Food and Drug Administration (FDA). She also created the North American Quality Council, responsible for coordinating quality issues, communication of regulatory issues and development of synergies and best practices among Novartis business units. In addition to the healthcare industry, Ann also has experience in the automotive and utilities industries. Ann has a bachelor's degree in Mechanical Engineering from Cornell University, and completed graduate coursework in Business at the University of Nebraska. Ann Bailey

Juergen Brokatzky-Geiger, Ph.D., is head of Human Resources for Novartis, a position he assumed in 2003. Brokatzky-Geiger has been a member of the Executive Committee of Novartis since January 1, 2005. Brokatzky-Geiger joined Ciba-Geigy Ltd. in 1983 as a Laboratory Head in the Pharmaceuticals Division. After a job rotation in Summit, New Jersey, he held positions of increasing responsibility in Research and Development (R&D) including Group Leader of Process R&D, Head of Process R&D, and Head of Process Development and Pilot Plant Operations. During the merger of Ciba-Geigy and Sandoz in 1996, Brokatzky- Geiger was appointed Integration Officer of Technical Operations. He later became the Head of Chemical and Analytical Development and served as the Global Head of Technical R&D from 1999 to August 2003. Brokatzky-Geiger graduated with a Ph.D. in chemistry from the University of Freiburg, Germany, in 1982.

Paul Herrling is Head of Corporate Research at Novartis, a position he assumed in November 2002. He is also Chairman of the Board of the Novartis Institute for Tropical Diseases (NITD) in Singapore, a long-term endeavor to advance medical research in tropical infectious diseases, which historically have received little drug-research funding. In addition, he oversees the Friedrich Miescher Institute (FMI) in Basel, Switzerland, the Genomics Institute of the Novartis Research Foundation (GNF) in California, USA and the Novartis Vaccines Institute for Global Health (NVGH) in Siena, Italy. Prior to his current position, Paul Herrling was Head of Global Research of Novartis Pharma and a member of the Pharma Executive Committee (PEC). In this capacity, he directed the integration of the research organizations of Sandoz and Ciba-Geigy following their merger in 1996 to form Novartis. Paul Herrling joined Sandoz Pharma in 1975 and held various positions in research at both Sandoz in Basel, Switzerland and Wander in Bern, Switzerland. In 1985, he became Head of the Sandoz Research Institute in Bern and Head of the Preclinical CNS Research Department at Sandoz Pharma in Basel. In 1992, he was made Head of Preclinical Research Basel for Sandoz Pharma and, in 1994, Head of Corporate Research. He is also a Professor of Drug Discovery Science at the University of Basel, Switzerland. In addition to scientific editing activities, he serves on several boards, most notably Board of Trustees of The Scripps Research Institute, University Council of the University of Basel and the Scientific Advisory Committee of the Drugs for Neglected Diseases Initiative (DNDi). Since January 2008 he is also the Vice-President of the ETH Board (Swiss Federal Institutes of Technology). Paul Herrling obtained his Ph.D. in 1975 from the University of Zurich, Switzerland and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA) in the USA. Paul Herrling

Thomas Wellauer, Ph.D., is Head of Corporate Affairs for Novartis, comprising the functions of Corporate Intellectual Property, Global Public Affairs, Corporate Health, Safety, Environment and Business Continuity Management, Group Purchasing, Corporate Risk Management, Corporate Integrity and Compliance, Corporate Security, International Coordination, Novartis Switzerland and the Novartis Foundation for Sustainable Development. He has been a member of the Executive Committee of Novartis since January 1, 2007. Wellauer joined Novartis in 2006 as Head of Corporate Affairs. He started his career with McKinsey and Company, Switzerland, becoming a Partner in 1991 and Senior Partner in 1996. In 1997, he was named CEO of the Winterthur Insurance Group, Switzerland, which later was acquired by Credit Suisse. At Credit Suisse he was a member of the Group Executive Board, initially responsible for the Group’s insurance business before becoming CEO of the Financial Services Division. Before joining Novartis, Wellauer headed and completed the Clariant Performance Improvement Program, a global turnaround project at the specialty chemicals maker. Wellauer graduated with a Ph.D. in systems engineering and an M.S. in chemical engineering from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He also holds an M.B.A. from the University of Zurich.

Thomas Werlen, Ph.D. is the General Counsel of Novartis and responsible for the Group’s legal affairs, a position he assumed in January 2006. He is Secretary to the Corporate Governance and Nomination Committee of the Board of Directors of Novartis. Thomas Werlen has been a member of the Executive Committee of Novartis since October 16, 2008. A member of the New York bar and the Zurich bar, Thomas Werlen started his professional career with the law firm Lenz & Staehelin in Zurich in 1990. After graduation from Harvard Law School in 1995, he joined Cravath, Swaine & Moore in New York. In 2001, he was elected a Partner in the London office of Allen & Overy. Thomas Werlen holds lic.iur and Ph.D. degrees in law from the University of Zurich and a master’s degree in law from Harvard Law School. Thomas Werlen is a member of the regulatory board of the SIX Swiss Exchange AG. March 2009 www.novartis.com

Function at Novartis AG Alexandre F. Jetzer has been a member of the Board of Directors since 1996. Other activities Alexandre F. Jetzer is a member of the supervisory board of Compagnie Financière Michelin, Switzerland, and of the board of the Lucerne Festival Foundation, Switzerland. He is a member of the International Advisory Panel on Biotechnology Strategy of the Prime Minister of Malaysia, a member of the Investment Advisory Council of the Prime Minister of Turkey and economic advisor to the Governor of Guangdong Province, China. He is also a member of the Development Committee of the Neuroscience Center of the University of Zurich, Switzerland. Professional background Alexandre F. Jetzer graduated with master’s degrees in law and economics from the University of Neuchâtel, Switzerland, and is a licensed attorney. From 1967 to 1980, he served as General Secretary of the Swiss Federation of Commerce and Industry (Vorort). Alexandre F. Jetzer joined Sandoz in 1980. In 1981, he was appointedmember of the Sandoz Group Executive Committee in his capacity as Chief Financial Officer. In 1990, he became Head of Management Resources and International Coordination. From 1995 to 1996, he was Chairman and Chief Executive Officer of Sandoz Pharmaceuticals Corporation in East Hanover, New Jersey, and at the same time served as President and CEO of Sandoz Corporation in New York. After the merger which created Novartis in 1996 until 1999, he was Head of International Coordination, Legal & Taxes and a member of the Executive Committee of Novartis. Permanent Novartis management or consultancy engagements Alexandre F. Jetzer has a consultancy agreement with Novartis International AG (Government Relations Support). January 2009 www.novartis.com

Andreas von Planta has been a member of the Board of Directors since 2006. He qualifies as an independent Non-Executive Director. He is a member of the Audit and Compliance Committee and the Corporate Governance and Nomination Committee. Other activities Andreas von Planta is Vice Chairman of Holcim Ltd. and of the Schweizerische National-Versicherungs-Gesellschaft AG, both in Switzerland, and is a member of the boards of various Swiss subsidiaries of foreign companies and other non-listed Swiss companies. He is a member of the board of editors of the Swiss Review of Business Law and is a former Chairman of the Geneva Association of Business Law. Andreas von Planta is Chairman of the regulatory board of the SIX Swiss Exchange AG Professional background Andreas von Planta holds lic. iur. and Ph.D. degrees from the University of Basel and an LL.M. from Columbia University School of Law, New York. He passed his bar examinations in Basel in 1982. Since 1983, he has been living in Geneva, working for the law firm Lenz & Staehelin where he became a partner in 1988. His areas of specialization include corporate law, corporate finance, company reorganizations, and mergers and acquisitions

Ann Fudge has been a member of the Board of Directors since 2008. She qualifies as an independent Non-Executive Director. She is a member of the Corporate Governance and Nomination Committee. Other activities Ann Fudge serves on the Board of Directors of General Electric, Connecticut, and on the Board of Overseers of Harvard University. She is also a Trustee of the Rockefeller Foundation and of Morehouse College, and Chair of the U.S. Programs Advisory Panel of the Gates Foundation. Professional background Ann Fudge received her B.A. from Simmons College and her M.B.A. from Harvard University Graduate School of Business. She is former Chairman and CEO of Young & Rubicam Brands. Before that, she served as President of the Beverages, Desserts and Post Division of Kraft Foods.

Function at Novartis AG Hans-Joerg Rudloff has been a member of the Board of Directors since 1996. He qualifies as an independent Non-Executive Director. He is Vice Chairman and Chairman of the Compensation Committee. He is also a member of the Chairman’s Committee and the Audit and Compliance Committee. The Board of Directors has appointed him as Audit Committee Financial Expert. Other activities Hans-Joerg Rudloff serves on a number of Boards of Directors, including the TBG Group (Thyssen-Bornemisza Group), Monaco, and RBC, Russia. In 2005, Hans-Joerg Rudloff became Chairman of the International Capital Markets Association (ICMA), Switzerland. In 2006, he joined the Board of Directors of Rosneft, a Russian state-controlled oil company, and became Chairman of the audit committee. He serves as the Chairman of the Board of Directors of Bluebay Asset Management Ltd., United Kingdom, and the Marcuard Group, Switzerland. He is also member of the board of directors of New World Resources B.V., Netherlands. In addition, Hans-Joerg Rudloff is a member of the advisory boards of Landeskreditbank Baden-Wuerttemberg and EnBW (Energie Baden-Wuerttemberg), both in Germany. Professional background Hans-Joerg Rudloff studied economics at the University of Bern. After graduating in 1965, he joined Credit Suisse in Geneva. He moved to the New York-based investment banking firm of Kidder Peabody Inc. in 1968. He later headed Swiss operations and was elected Chairman of Kidder Peabody International. In 1978, he became a member of the Board of Directors of Kidder Peabody Inc, United States. In 1980, he joined Credit Suisse First Boston, Switzerland, was elected Vice Chairman in 1983 and became Chairman and CEO in 1989. From 1986 to 1990, Hans-Joerg Rudloff was also a member of the executive board of Credit Suisse in Zurich, in charge of all securities and capital-market departments. From 1994 to 1998, Hans-Joerg Rudloff was Chairman of MCBBL in Luxembourg. In 1994, he was appointed to the Board of Directors of Sandoz AG. In 1998, Hans-Joerg Rudloff joined Barclays Capital, United Kingdom, where he is presently Chairman. January 2009 www.novartis.com

Marjorie M. Yang has been a member of the Board of Directors since 2008. She qualifies as an independent Non-Executive Director. She is a member of the Compensation Committee. Other activities Marjorie M. Yang is Chairman of the Esquel Group, Hong Kong. She currently sits on the Boards of Directors of Swire Pacific Ltd., CLP Holdings and The Hong Kong and Shanghai Banking Corporation Ltd., all in Hong Kong. She is also a member of the National Committee of the Chinese People’s Political Consultative Conference, Chairman of the Textile and Clothing Sector Committee, Vice Chairman of the China Association of Enterprises with Foreign Investment and a member of the M.I.T. Corporation. Marjorie M. Yang is on the Board of Dean’s Advisors of Harvard Business School. Professional background Marjorie M. Yang graduated with a B.S. in mathematics from M.I.T. and holds an M.B.A. from Harvard Business School. From 1976 to 1978, she was an associate in Corporate Finance, Mergers and Acquisitions with the First Boston Corporation in New York. In 1979, she returned to Hong Kong and helped create Esquel. She has been Chairman of the Esquel Group since 1995.

Function at Novartis AG Pierre Landolt has been a member of the Board of Directors since 1996. He qualifies as an independent Non-Executive Director. He is a member of the Corporate Governance and Nomination Committee. Other activities Pierre Landolt is currently Chairman of the Sandoz Family Foundation and a Director of Syngenta AG. He is a partner with unlimited liabilities of the private bank Landolt & Cie. Pierre Landolt serves, in Brazil, as President of the Instituto Fazenda Tamanduá, the Instituto Estrela de Fomento ao Microcrédito, AxialPar Ltda and Moco Agropecuaria Ltda. In Switzerland, Pierre Landolt is the Chairman of Emasan AG and Vaucher Manufacture Fleurier SA and the Vice-Chairman of Parmigiani Fleurier SA. He is a Director of EcoCarbone SA and Amazentis SA and was formerly Chairman of the CITCO Group (1995-2005). He is also Vice-Chairman of the Montreux Jazz Festival Foundation. Professional background Pierre Landolt graduated with bachelor’s degree in law from the University of Paris-Assas. From 1974 to 1976, he worked for Sandoz Brazil SA. In 1977, he acquired an agricultural estate in the semi-arid northeast region of Brazil and, over several years, converted it into a model farm in organic and biodynamic production. Since 1997 Pierre Landolt has been Associate and Chairman of AxialPar Ltda, Brazil, an investment company focused on sustainable development, with investments in fish farming, soybean for human consumption and organic vegetable. In 2000, he co-founded EcoCarbone SA, France, a company active in the design and development of carbon-sequestration processes in Asia, Africa, South America and Europe. In 2007, he co-founded Amazentis SA, a start-up company active in the convergence space of medication and nutrition. In addition to his private activities, Pierre Landolt has been President of the Sandoz Family Foundation since 1994 and oversees the development of the foundation in several investment fields, inter alia hotel, watch making and telecommunications. January 2009 www.novartis.com

Rolf M. Zinkernagel is a Venture Partner and Scientific Partner of Aravis. He is Professor and former Head of the Institute of Experimental Immunology, Department of Pathology at the University of Zurich. He is specialized in infectious diseases and immunopathology and a pioneer in research on self-nonself discrimination in immunology. Rolf M. Zinkernagel was elected to the Board of Directors of Novartis AG in 1999. Until 2003 he was a member of the Board of Directors of Cytos Biotechnology. He is member of scientific advisory boards and science consultant to various life science companies. Among many other honors and awards for his contributions to science Rolf M. Zinkernagel received the Nobel Prize in Medicine in 1996.

Ulrich Lehner has been a member of the Board of Directors since 2002. He qualifies as an independent Non-Executive Director. He serves as Vice Chairman, Lead Director and Chairman of the Corporate Governance and Nomination Committee. He is also a member of the Audit and Compliance Committee, the Chairman’s Committee and the Compensation Committee. The Board of Directors has appointed him as Audit Committee Financial Expert. Other activities Ulrich Lehner is Chairman of the supervisory board of Deutsche Telekom AG and serves as a member of the supervisory board of E.ON AG, of Thyssen Krupp AG, of HSBC Trinkaus & Burkhardt KGaA and of Porsche Automobil Holding SE, all in Germany. He is also a member of the shareholders’ committee of Henkel AG & Co. KGaA and of Oetker KG, both in Germany. Professional background Ulrich Lehner graduated in business administration and mechanical engineering from the Darmstadt University of Technology in 1975. From 1975 to 1981, he was an auditor with KPMG Deutsche Treuhand-Gesellschaft AG in Duesseldorf. In 1981, he joined Henkel KGaA. After heading the Controlling Department of Fried. Krupp GmbH in Germany from 1983 to 1986, Ulrich Lehner returned to Henkel as Finance Director. From 1991 to 1994, he headed the Management Holding Henkel Asia-Pacific Ltd. in Hong Kong, and from 1995 to 2000, served as Executive Vice President, Finance/Logistics (CFO), of Henkel KGaA. From 2000 to 2008, Ulrich Lehner served as Chairman of the Management Board of Henkel KGaA.